Objectives
toxicity
DISEASE
The primary objective of this study was to compare the number of COVID19 patients who progressed to severe disease (defined as grade 5 or more of the OSCI) in the control vs the experimental arm.Secondary objectives were to compare ICU admission and length of stay, days of hospitalization, and mortality at 28 days, 6 months and 12 months after randomization between study arms. Also, we described the toxicity profile of the combination of ruxolitinib plus simvastatin.Finally, we aimed to study the evolution of cytokines in plasma along treatment, define a cytokine signature in plasma predictive of COVID-19 outcome and to develop a Machine Learning (ML) algorithm able to predict patient deterioration.